Solti Breast Cancer Research Group
Clinical trials sponsored by Solti Breast Cancer Research Group, explained in plain language.
-
New combo targets tough breast cancer in early trial
Disease control CompletedThis early-phase study tested a new combination of drugs for people with a specific type of advanced breast cancer (HER2-positive with a PIK3CA mutation). The goal was to find the safest dose of the new drug (ipatasertib) when added to two standard treatments. Only 17 people took…
Phase: PHASE1 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated May 17, 2026 13:08 UTC
-
New combo therapy shows promise for tough breast cancers
Disease control CompletedThis study tested a combination of two drugs, T-VEC and atezolizumab, in 28 women with early-stage breast cancer that still had tumor left after standard chemotherapy. The goal was to see if this treatment could shrink or eliminate the remaining cancer before surgery. The approac…
Phase: EARLY_PHASE1 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New test may predict who benefits from targeted breast cancer drug
Knowledge-focused CompletedThis study tested a new lab test (RAD51-foci) to see if it can predict whether the drug olaparib will shrink tumors in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). The study involved 65 participants and…
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Knowledge-focused
Last updated May 17, 2026 13:03 UTC